a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 15/237,364, relating to "miRNA Expression Signature in the Classification of Thyroid Tumors." The allowed patent claims a method of classifying a thyroid lesion sample obtained by fine needle aspiration as malignant or benign, through a classifier algorithm that utilizes the expression profile of microRNAs detected by real time polymerase chain reaction (RT-PCR).
"We continue to fortify our patent portfolio around the Reveal assay, further protecting and distinguishing it from would-be competitors and firmly establishing Rosetta's leading intellectual property position in microRNA diagnostics," stated Kenneth A. Berlin , President and Chief Executive Officer of Rosetta Genomics .
March 17th, a company engaged in developing and commercializing new diagnostic tests based on various genomics markers, said Thursday that the 1-for-12 reverse stock split of its share capital has taken effect.
Immediately subsequent to the reverse stock split, there will be about 1,870,000 of the company's ordinary shares issued and outstanding.
Nothing I state is intended to be a recommendation to buy or sell, opinion only. Readers are solely responsible for how they use the information.